JAY T FLATLEY
CIK 1189130 · Chairman and Acting CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$43.24M
Companies
6
Total Filings
354
Lifetime Open-Market Net
-$491.98M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RIVN | Director | 179,515 | $16.80 | $3.01M | $2.75M | 8 | 2026-06-23 |
| DNLI | Director | 358,941 | $24.42 | $8.77M | $0 | 12 | 2026-06-05 |
| Zymergen Inc. (ZY) Delisted | Chairman and Acting CEO | 0 | $2.43 | $0 | $1.00M | 4 | 2022-10-19 |
| COHR | Director | 856 | $248.66 | $212.8K | -$2.07M | 22 | 2022-07-01 |
| ILMN | Director | 152,433 | $204.99 | $31.25M | -$494.38M | 303 | 2021-05-20 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 0 | — | — | $724.4K | 5 | 2018-03-07 |
Recent Filings · Page 12 of 36
354 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-08-17 | ILMN | Mixed | — | -$2.48M | EDGAR |
| 2017-08-03 | ILMN | Mixed | — | -$2.11M | EDGAR |
| 2017-07-20 | ILMN | Mixed | — | -$1.50M | EDGAR |
| 2017-07-07 | ILMN | Mixed | — | -$1.53M | EDGAR |
| 2017-06-22 | ILMN | Mixed | — | -$2.15M | EDGAR |
| 2017-06-19 | Juno Therapeutics, Inc. (JUNO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-08 | ILMN | Mixed | — | -$2.88M | EDGAR |
| 2017-06-02 | ILMN | Sell (S) | −3,320 | -$599.4K | EDGAR |
| 2017-05-26 | Juno Therapeutics, Inc. (JUNO) Delisted | Buy (P) | +20,000 | $495.2K | EDGAR |
| 2017-05-25 | ILMN | Mixed | — | -$2.09M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.